Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation
Leukemia Research(2018)
摘要
•Deregulation of innate immune signaling is important in the pathogenesis of MDS.•Ruxolitinib is active in previously treated lower-risk MDS with NF-kB activation.•Reduction in pp65 expression may correlate with response duration.
更多查看译文
关键词
Myelodysplastic syndromes,NF-kB,Toll-like receptors,TNF-α,IL-8
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要